Herpes Zoster Therapeutics - Pipeline Assessment And Market Forecasts To 2017

The herpes zoster market is predicted to witness a significant rise over the next few years following the launch of two vaccines in major markets. In 2006 Merck launched zostavax, which is the only vaccine approved in the US for the prevention of herpes zoster. It is awaiting its launch in other major markets, expected in 2011. GlaxoSmithKline Biologicals GSK1437173A vaccine is under Phase III trial and is expected to launch in the coming years. GlobalDatas analysis suggests that the global herpes zoster market was worth $651m in 2010. The market is forecast to show a rise in compound annual growth rate (CAGR) of 11%, following the patent launch of vaccines GSK1437173A and V212 (Zostavax) in major markets.

GlobalDatas pipeline analysis revealed that there are nine candidates in the various stages of clinical development. Phase II has five pipeline molecules. There is only one molecule in Phase I. However the molecules ARYS-01 by aRigen Pharmaceuticals, EPB-348 by Epiphany Biosciences, and ASP2151 by Astellas Pharma Inc. are expected to be promising candidates for the herpes zoster market. The pipeline molecules differ from each other in terms of mechanism of action, and can further capture the current market on approval.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Herpes-Zoster-Therapeutics-Pipeline-Assessment-and-Market-Forecast-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

prescribed by medical practitioners to treat the symptoms of the disease. To reduce the risk factor and prevent the disease, adults above 60 years of age are vaccinated with zostavax, which is a live attenuated vaccine developed by Merck & Co.
The unmet need for the herpes zoster therapeutics market was estimated to be approximately $87m, and for the prophylactic market it is estimated to be $79m. Currently there are significant patient populations that are likely to switch over to new products with better efficacy and safety.

GlobalData, the industry analysis specialist, has released its new report, Herpes Zoster Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global herpes zoster market. The report identifies the key trends shaping and driving the global herpes zoster market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global herpes zoster sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Herpes-Zoster-Therapeutics-Pipeline-Assessment-and-Market-Forecast-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782